The INK4A locus encodes two tumor suppressor genes, p16
Introduction
The tumor suppressor p16
INK4A (also called CDKN2A) regulates the cell cycle by inhibiting the cyclin Ddependent kinase (CDK) 4 or CDK6 complex, thereby preventing phosphorylation of retinoblastoma (pRB) proteins and its regulation of G 1 exit (Ortega et al., 2002) . Inactivation of p16
INK4A , which occurs via gene deletion (Cheng et al., 1994; Jen et al., 1994) , mutation (Caldas et al., 1994; Hussussian et al., 1994; Okamoto et al., 1994) and hypermethylation of the promoter region Schutte et al., 1997) , has been reported in a variety of tumors. In addition to cancer, the importance of p16
INK4A
in the regulation of senescence of normal cells has been also recognized (Kim and Sharpless, 2006) . In a previous report from our group, we demonstrated the universal inactivation of both p16
INK4A and p15 INK4B in T-cell acute lymphoblastic leukemia (T-ALL) at the DNA, RNA or protein levels (Omura-Minamisawa et al., 2000) . The high frequency of p16
INK4A inactivation suggests deregulation of this gene or that the p16
INK4A regulatory pathway is important in the pathogenesis of T-ALL (OmuraMinamisawa et al., 2000) . In contrast to inactivation in T-ALL, we observed an increase in p16
INK4A expression in advanced stage neuroblastoma (Diccianni et al., 1996; Omura-Minamisawa et al., 2001) , demonstrating the complexity of this pathway in tumor pathogenesis.
In mammalian organisms, the INK4 family consists of four members: p16
INK4A , p15
INK4B
, p18 INK4C and p19
INK4D
, all of which have similar biochemical properties in inhibition of cell growth and in tumor suppression (Serrano, 1997; Komata et al., 2003) . The INK4A locus is localized to chromosome 9p21 and generates at least three transcriptional variants, p16
INK4A , p14 ARF (alternative reading frame) and p12 (Robertson and Jones, 1999; Ortega et al., 2002) . p16
INK4A and p14 ARF are transcribed from distinctive first exons (exon 1a and exon 1b, respectively) spliced onto common exons 2 and 3. The coding frame of p14
ARF is offset by a single base pair relative to p16
INK4A
, resulting in the translation of a unique protein Stone et al., 1995; Ortega et al., 2002) . The p12 transcript shares exon 1a with p16
INK4A , but transcribes contiguously 274 bp into intron 1, utilizing an alternative splice donor site within intron 1 before splicing onto p16
INK4A exons 2 and 3 (Robertson and Jones, 1999) . A stop codon in the newly transcribed intron 1 results in a putative protein comprised predominantly of p16
INK4A exon 1. With the exception of pancreas, which does not express p14 ARF , the expression patterns of p16
INK4A and p14 ARF have been shown to be nearly identical in all normal tissues of both human and murine Stone et al., 1995) . On the other hand, the p12 transcript appears to be expressed only in human pancreas (Robertson and Jones, 1999) .
Although p16
, p14 ARF and p12 are generated from the same INK4A locus and all of them are able to suppress cell growth, their mechanisms of cell-cycle regulation are distinct. The p16
INK4A protein, containing four ankyrin repeats (Tevelev et al., 1996; Byeon et al., 1998) , binds to CDK4 and CDK6 and results in the inhibition of cyclin D/CDK4 or CDK6 kinase activity, the inhibition of pRb protein hyperphosphorylation and the release of transcription factors such as E2Fs, resulting in G 1 phase cell-cycle arrest. The p14 ARF protein acts as a tumor suppressor and inhibitor of cell growth by interacting with human MDM2 and preventing the degradation of the p53 tumor suppressor protein (Zhang et al., 1998; Ortega et al., 2002) ; p14 ARF contains no ankyrin repeat units. The p12 protein, containing only 1.5 of the four ankyrin repeats found in p16
protein, does not interact with CDK4 but is capable of inhibiting cell growth in a pRb-independent manner (Robertson and Jones, 1999) .
In this study, we report the discovery of another novel transcriptional variant of p16 INK4A , termed p16g, which was highly expressed in a primary T-ALL patient and a neuroblastoma cell line at both the transcriptional and translational levels, and expressed at low levels in other p16
INK4A -expressing primary T-ALL and B-lineage-ALL patient samples. Functionally, p16g interacts with CDK4, inhibits CDK4 kinase activity and suppresses cell proliferation. Our finding of another structural and functional variant of p16
INK4A further demonstrates the complexity of the INK4A locus and represents yet another mechanism through which the INK4A locus acts on cell-cycle regulation.
Results
Identification of p16g, an alternative transcript of p16 INK4A distinct from p14 ARF and p12 In our investigations of p16
INK4A expression by reverse transcription-PCR (RT-PCR) in T-ALL and neuroblastoma (Diccianni et al., 1996 (Diccianni et al., , 1999 (Diccianni et al., , 2004 , we observed that a primary T-ALL sample and a neuroblastoma cell line, Be2C, expressed a second band approximately 200 bp larger than p16
INK4A in addition to p16
INK4A (Figure 1a ). Direct sequence analysis revealed that this extra cDNA fragment was identical to p16
INK4A
through the first and second exons, but had an additional 197 bp spliced in frame between exons 2 and 3. We referred to this additional exon as 'exon 2g' to distinguish it from exon 1a and exon 1b of the INK4A locus and thereby named this novel transcript p16g. Analysis of the genomic sequence of p16
INK4A revealed that exon 2g was derived from sequences located in intron 2, 2131 bp downstream of the splice site from the p16 INK4A exon 2 (Figure 2a ). No mutations in any of the coding regions of p16
INK4A or p16g were observed. We, however, observed a C-T homozygous change 6 bps downstream of 3 0 end of the gamma exon in genomic DNA of both Be2C cell line and the primary T-ALL sample that expressed p16g, but not found in four other p16
INK4A transcript-expressing samples. An additional C-G base change 3 bp upstream of the 5 0 splice region of exon 3 was identified in DNA from the Be2C cell line only. The significance of these genomic changes remains unclear. p16 INK4A encodes a protein of 156 amino acids with a predicted molecular weight of 16 533 Da. The amino-acid INK4A transcript and an additional transcript (p16g) which is 200 bp larger than the wild-type transcript is noted; lane 3, (wtÀ/gÀ): the p16sequence deduced from p16g shows that p16g protein is composed of 167 amino acids with a predicted molecular weight of 17 883 Da, for which stop codon is in the exon 2g instead of exon 3 for p16 INK4A (Figure 2 ). The first 152 amino acids of both proteins are identical, while the Cterminus of the p16g protein is comprised of a unique 15-amino-acid sequence created by the in frame splicing of exon 2g (Figure 2b) . Consistent with this, we detected two p16
INK4A immunoreactive proteins by western blot from lysates of Be2C cells; the 16 kDa wild-type species and an approximately-18 kDa p16g protein present only in Be2C cells (Figure 1b) .
As stated above, p16g was discovered using primers that detect the full-length p16
INK4A . By this analysis, only the two aforementioned samples expressed this novel transcript. However, we considered that if p16g expression was very low in other samples, its expression may not be detected using full-length p16
INK4A primers. We thus chose to rescreen primary leukemia samples and neuroblastoma cell lines with intron-spanning PCR primers designed to amplify selectively exon 2g (see Materials and methods section). Using g-specific primers, we observed low but detectable levels of p16g in 14 of 27 p16
INK4A positive T-ALL samples, though only one sample expressed p16g high enough to be detected using full-length p16
INK4A primers ( Figure 1c ). In B-ALL, 8 of 8 p16
-positive samples analysed had detectable levels of p16g, while in acute myeloid leukemia, 2/4 p16
-positive samples analysed harbored detectable levels of p16g (data not shown). In contrast to the frequent detection of p16g in leukemia samples, of 18 neuroblastoma cell lines investigated, only Be2C expressed p16g, even though fully one-third of the cell lines expressed p16
INK4A (Diccianni et al., 1996 (Diccianni et al., , 1999 . The neuroepithelial cell line, SK-N-MC, which also expresses p16
INK4A and p15 INK4B (despite partial p15
INK4B
promoter hypermethylation, unpublished data), did not express p16g either. We also investigated other tumor cell lines and normal tissue samples for p16g expression (Figure 1c ). Tumor cell lines from colon (N ¼ 3), melanoma (N ¼ 4) and osteosarcoma (N ¼ 2) varied in their expression of detectable levels of p16g using g-specific primers. In RNA from two of 13 normal mononuclear cell samples, p16g was very low but detectable. As one might expect, p16g was detected only in p16
INK4A -expressing tumor cell extracts. No p16g was detected in normal RNA pooled from liver, pancreas, thymus or bone marrow, but g-specific primers demonstrated barely detectable levels of p16g in pooled RNA from colon, spleen and prostate.
Biophysical properties of p16g
As demonstrated by nuclear magnetic resonance (NMR) structure analysis, p16
INK4A protein is composed of four ankyrin repeat units, each comprised of a helix-turnhelix motif linked by b-hairpin-containing loops (Byeon et al., 1998) . The ankyrin repeats stack to form a supercoil structure, whereas the b-hairpins as well as some helical residues align to form a functional binding surface for protein-protein interactions (Li et al., 2006) . To compare the biochemical and biophysical properties of p16g protein with those of p16
INK4A and the closely related p18
INK4C (Tevelev et al., 1996; Li et al., 1999 Li et al., , 2000 , p16g was overexpressed in Escherichia coli as a GST-tagged protein and purified to homogeneity after INK4A , p16g, p12 and p14 ARF . p16
INK4A and p14 ARF are transcribed from distinctive first exons (exon 1a and exon 1b, respectively) which are spliced onto common exons 2 and 3. The p16g transcript harbors a 197 bp inserted in frame between exons 2 and 3 of the wild-type p16
INK4A gene. This insert is derived from a cryptic exon located in intron 2, 2131 bp downstream of exon 2, termed exon 2g. The stop codon of p16
INK4A
(marked by **) is in the exon 3 and the stop codon of p16g (marked by *) is in the exon 2g. p12 transcript shares exon 1a (the green region) with p16
INK4A , but transcribes contiguously 274 bp (the yellow region) into intron 1, utilizing an alternative splice donor site within intron 1 before splicing onto p16
INK4A exons 2 and 3. X1b, exon 1b. X1a, exon 1a. X2, exon 2. X2g, exon 2g. X3, exon 3. (b) The nucleotide and protein sequences of p16g. The GenBank accession number of p16g is DQ318021. The nucleotide sequences of exon 2g are shown in italic. The joints between exon 1 and exon 2, exon 2 and exon 2g, exon 2g and exon 3 are labeled with green, blue and magenta, respectively. The amino-acid sequences are shown in bold. wt/g, the common sequences of p16
INK4A and p16g; g, p16g only; wt, p16
INK4A only. *, the stop codon of 16g. **, the stop codon of p16
INK4A .
p16c: a novel transcriptional variant of p16
removal of the tag. The molecular weight of this protein was verified by MALDI. Using NMR to explore the structural properties of p16g protein, we observed that p16g showed substantial line broadening of the NMR signal at a concentration as low as 0.1 mM (data not shown), which indicates that the tendency to aggregate is greater for p16g than for p16
INK4A and p18 INK4C (which start to aggregate at 0.4 and 0.6 mM, respectively) (Tevelev et al., 1996; Byeon et al., 1998; Li et al., 1999) . Circular dichroism (CD) was next used to characterize the secondary structure and the conformational stability of p16g protein. As shown in Figure 3a , the CD spectrum of full-length p16g from 190 to 260 nm was very similar to that of other ankyrin repeat proteins including p15 INK4B p16 INK4A and p18
INK4C
and it had two minimums at 207 and 220 nm, indicating that the p16g protein contained a-helices. A quantitative analysis of these CD data using the method of Andrade et al. (1993) suggests that there is no significant difference in the a-helical content of p16g and p16
INK4A
(data not shown). Guanidinium hydrochloride-induced unfolding of p16 INK4A , p18 INK4C and p19 INK4D have been shown to follow a two-state equilibrium unfolding transition model (Li et al., 2006) . However, the unfolding data for p16g did not fit this model (Figure 3b) . A platform in the CD denaturation curve of p16g protein is seen when the concentration of guanidinium hydrochloride was in the range of 0.5-1.5 M. This indicates that, besides the native and completely unfolded states, there is an intermediate state during guanidinium hydrochloride-induced denaturation of p16g protein (Pace, 1986) . Therefore, the C-terminus extension of p16g protein may be influencing the folding and unfolding of the protein.
p16g protein bound to CDK4 and inhibited the kinase activity of CDK4/cyclinD2 similar to p16
INK4A is known to regulate the cell cycle by binding to the D-type cyclin/CDK4/6 complexes through interactions with CDK4/6 (Xiong et al., 1993) . To examine the physical interaction between CDK4 and p16g protein, we cloned the full-length cDNA of p16
INK4A and p16g by RT-PCR and constructed p16
INK4A and p16g-expressing plasmids, named pcp16wt and pcp16g, respectively, and transiently expressed these plasmids in three p16
INK4A -negative cell lines, A549 lung cancer, Be2C/ADR5 neuroblastoma (Diccianni et al., 1996 (Diccianni et al., , 1999 and U2OS osteosarcoma; their expression at the protein level was confirmed by western blot (Figure 4a , lower panel). To examine the physical interaction between CDK4 and p16g protein, cell lysates of A549 cells, Be2C/ADR cells and U2OS cells that were transiently transfected with pcp16g plasmid (or pcp16wt as the control) were immunoprecipitated with a-CDK4 antibody and probed for p16
INK4A and p16g expression by western blot analysis. As shown in Figure 4a (upper panel), p16g protein was present in the immunoprecipitate complexes from all three cancer cells, demonstrating that p16g protein was able to interact physically with CDK4.
We further quantitatively evaluated the CDK4-binding affinity of p16g using a yeast two-hybrid system in which CDK4 was fused to the LexA-DNA binding domain while p16g protein was fused to the transcription activation domain. After transformant selection, the CDK4-binding affinity of p16g protein was determined by liquid b-galactosidase enzymatic assay. Yar1, a yeast protein containing three ankyrin repeats, was used as negative control, and human p16
INK4A and p18
INK4C proteins were used as positive controls. As shown in Figure 4b , human p16
, p18
INK4C and p16g
(p16) and p18 INK4C (p18). Samples containing 1 mM recombinant p16g, p16
INK4A , p15 INK4B and p18 INK4C proteins were analysed on an AVIV CD Spectrometer as described in Material and methods section. For each sample, the scan number is 10, and the mean value from 10 scans was used to calculate the molar ellipticity per residue as described. Similar to p16
INK4A , p15 INK4B and p18
INK4C
proteins, p16g protein exhibits a spectrum with two minimums at 207 and 220 nm, respectively, indicative of the presence of a-helices in p16g. (b) Guanidinium hydrochloride titration of p16g and p16 INK4A . Samples containing 7.5-10.0 mM proteins were incubated with different amounts of guanidinium hydrochloride on ice overnight and then equilibrated at 201C just before CD analysis. The rotation at 222 nm, an indicator of the existence of a-helical secondary structure was measured, and the exact concentrations of guanidinium hydrochloride were determined using its reflex index. Solid circle: p16
INK4A ; empty circle: p16g. Assays were performed in duplicate, and the expected experimental error was 75-10%.
While p16
INK4A shows a two-state unfolding transition, fitting of p16g data to a two-state model is poor, suggesting that the unfolding of p16g deviates from the two-state model. INK4A proteins) is set as 100% CDK4 activity, and the incorporation for the sample without CDK4 is used as background. The relative kinase inhibition activity is defined as (1-CDK4 activity with p16g or p16
INK4A /CDK4 activity without inhibitor) Â 100%. (Li et al., 1999) , suggesting that the C terminal extension of p16g protein did not significantly change its CDK4-inhibitory activity. Taken together, these findings strongly suggest that p16g is biochemically similar to p16
INK4A in CDK4 binding and inhibition, which is consistent with the observation that the C-terminus of p16
INK4A contributes little to CDK4 binding and inhibition (Byeon et al., 1998; Russo et al., 1998; Li et al., 1999) .
p16g caused cell-cycle arrest by inhibiting the pRb/E2F pathway Upon hyperphosphorylation of pRb by CDK/cyclin complexes, E2F transcription factors are released from pRB/E2F complexes and freed to activate their downstream target genes, leading to cell-cycle progression (Dyson, 1998) . To examine the effect of p16g on the CDK/cyclin/pRb/E2F pathway, we utilized the 3 Â WT E2F-Luc reporter plasmid, which contains three E2F response elements followed by a firefly luciferase reporter gene (Krek et al., 1993) , to carry out transient cotransfections with pcp16wt or pcp16g plasmids. As shown in Figure 5a , p16g was able to repress the E2F-response with an efficacy equivalent to that of p16
INK4A
in both U2OS and A549 cells, suggesting that p16g and p16
INK4A were repressing the release of E2F transcription factors from pRB/E2F complexes in a similar manner.
To compare the growth suppressive effect of p16
and p16g, we transiently transfected p16
-negative U2OS cells with pcp16wt or pcp16g plasmids along with phrGFP-C as a transfection marker, in a ratio of 10:1. After transfection, the cells were stained with Hoechst 33342 (for DNA staining) and analysed by flow cytometry to determine the cell cycle profiles of green fluorescent protein (GFP)-positive cells. The expression of p16
INK4A or p16g resulted in a similar accumulation of cells in the G 0 /G 1 phase, while the percentage of cells in S phase decreased relative to the vector control ( Table 1) , demonstrating that p16g and p16
INK4A function similarly in arresting cell-cycle transition at the G 0 /G 1 phase.
To examine further the capability of p16g on arresting the growth of p16
INK4A -negative cells, we performed the colonogenic assay. After transfection with p16g, U2OS cells were plated at 3 Â 10 3 cells in the 60 mm dishes and selected with 500 mg/ml G418 for 2 weeks. The number of resistant colonies of vector-transfected cells was 144710.8. In contrast, the number of surviving colonies in the p16
INK4A -or p16g-transfected cells was less than 15 ( Figure 5b ). This result demonstrates that p16g, like p16
INK4A , is a potent regulator of cell growth.
Discussion
We describe here the discovery and the characterization of a novel alternatively spliced transcript of p16 INK4A , which we have designated as p16g, that was very highly expressed in a neuroblastoma cell line and in a primary T-ALL sample. At much lower levels, we detected p16g in many cell lines and primary tumor samples, suggesting that low level expression may be common in many Cells seeded in 35-mm dish were transfected with 2.5 mg of the indicated plasmid (Vector, pcDNA3.1(+); p16WT, pcp16wt; p16g, pcp16g) and 0.25 mg of phrGFP-C. Two days after transfection the cells were prepared for flow cytometry. Indicated is the percentage of GFP-positive cells present in the respective phase of the cell-cycle. The percentages and s.d. shown here were generated by three independent experiments. *Po0.05, significant difference from vector control. INK4A . In addition, p16g induced G 0 /G 1 arrest and suppressed cell growth in colony formation assay. We also observed that p16g repressed the E2F-response reporter with an efficacy equivalent to that of p16 INK4A in both A549 and U2OS cell lines, suggesting that, like p16
INK4A , the growth inhibitory function of p16g is pRb dependent.
Partial deletions and mutations have been implicated in the generation of splicing variants of p16 INK4A , with most appearing to be tissue specific. In ovarian cancer and in liver cancer, hemizygous deletions of the p16
INK4A
gene resulted in tumor samples that expressed full length and aberrant transcripts (Suh et al., 2000a, b) . p16
promoter hypermethylation has also been implicated in the generation of alternative p16
INK4A transcripts in hepatocarcinoma (Cho et al., 2003) . Previous studies by our group revealed no p16
INK4A promoter hypermethylation in T-ALL or Be2C (Diccianni et al., 1996; Batova et al., 1997) . In gastric cancer, a number of aberrant p16
INK4A species that have lost parts of exons 1 and 2 and/or contain insertions of intron 2 have been reported (Chen et al., 1997) . While there was no information on the functional consequence of this alteration, the loss of the ankyrin repeat units of exon 2 would almost certainly result in a loss of CDK inhibitory function. None of these alternative transcripts involved exon 2g. In melanoma, an intron 2 'mutation' silenced the wildtype exon 2 donor splice site, generating two new alternative transcripts that read into intron 2 (Harland et al., 2001) . Although functionally uncharacterized, the putative protein would harbor all four ankyrin repeats of p16
INK4A and would be expected to possess kinase inhibition activity if translated. None of these sequence alterations map to regions close to exon 2g. In our study, although no mutations were detected in exon 2, exon 2g or exon 3 of the two samples highly expressing p16g, we did find a C-T homozygous change 6 bp downstream of the 3 0 end of the gexon in the genomic DNA of both samples and an additional C-G base change 3 bps upstream of the 5 0 splice region of exon 3 in Be2C cell line. In light of the close proximity of these two mutations to the exon/intron boundaries, they may affect cis-regulatory elements such as intronic splicing enhancer and intronic splicing silencer (Aretz et al., 2004; ElSharawy et al., 2006; Yu et al., 2006) . Further investigation will be necessary to enlighten this issue in the future.
The function of these aberrant transcripts in cancer is not clear. A number of them lack ankyrin repeats and the ability to bind CDK4, though this may not necessarily preclude a given protein from having regulatory activity. The unique reading frame of p14 ARF , its lack of ankyrin repeat units and its inability to bind CDKs initially suggested to investigators that it was an inactive splice variant of p16
. However, p14
ARF has proved to be a potent cell-cycle regulator by mechanisms independent of CDK binding (Quelle et al., 1995) . Thus, it would be premature to conclude that the alternative species that lack ankyrin repeat units lack regulatory activity. Notably, several aberrant transcripts of p16
INK4A identified in hepatocarcinomas retained the capacity to inhibit cell growth in in vitro assays (Cho et al., 2003) . ARF has now been reported to interact physically with more than 25 other proteins. These include proteins involved in ribosome biogenesis, transcriptional regulation, the DNA-damage response, apoptosis and autophagy, most of which remain controversial and poorly understood (Sherr, 2006) . Recently, p16
INK4A protein has been shown to interact directly with band 3, also known as anion exchanger1 (AE1), and to facilitate the movement of band 3 to plasma membrane with increased anion transport activity, which is suggested to be related to regulation of cell proliferation, senescence and homeostasis (Fu et al., 2005) . In addition, while the p12 protein did not interact with CDK4, in vitro transfection of cells with p12 demonstrated a pRb-and p53-independent ability to suppress cell growth (Robertson and Jones, 1999) . This suggests that the INK4A locus may have a large and varied capacity to regulate cell growth distinct from the well-known p16
INK4A and p14 ARF genes. In mammalian cells, nonsense-mediated mRNA decay (NMD) has evolved as a quality-control process to degrade abnormal mRNAs produced by aberrant alternative splicing and which contain premature stop codons 50 or more nucleotides upstream of the final intron position (Hillman et al., 2004) . It is noteworthy that the p16g mRNA has molecular characteristics that could make it an attractive target for NMD; that is, the stop codon of p16g lies in the exon 2g, which is inside of the last intron of p16 INK4A , and is located at 150 nucleotides upstream of the 5 0 end of exon 3. This observation raises the possibility that cells with normal p16
INK4A gene may express both p16 INK4A and p16g mRNAs; however, only p16
mRNA remains detectable because p16g mRNA is degraded by NMD before being translated. This would be consistent with the extremely low levels of p16g expression detected in some normal cells. Thus, the low but easily detectable levels of p16g expression in many of the p16
expressing tumor cells might be the consequence of a leakage or deregulation of the NMD mechanism. Whether NMD process is altered in some malignant cells awaits further investigation.
In summary, we have reported the identification and molecular and functional characterization of a novel alternative transcript of p16
INK4A we have termed p16g, which is formed by the in-frame splicing of a portion of intron 2 to p16
INK4A exons 2 and 3. p16g functions indistinguishably from wild-type p16
in CDK interaction and inhibition, cell-cycle arrest and inhibition of cell growth. We conclude that p16g is a cell-cycle INK4A and p14 ARF (Fu et al., 2005; Sherr, 2006) , our discovery of yet another transcriptional variant further adds to the complexity of the regulatory control and biological functions of INK4 locus. Our NMR and CD data showing altered properties of p16g, raises the intriguing possibility that p16g and p16
INK4A may differ in their interaction with proteins other than CDK4/6. Further investigation to pursue this possibility may be warranted.
Materials and methods
Human primary leukemia samples Heparinized bone marrow or peripheral blood samples were obtained at diagnosis from patients with B-precursor ALL at the University of California, San Diego, USA and T-ALL patients enrolled in Pediatric Oncology Group Protocols #9000 and #9400 (ALL Biology Study). Samples are fully encoded to protect patient confidentiality and conform to HIPAA standards and are utilized under a University of California, San Diego-approved IRB protocol (#041429). Tumor cell content was determined to be 80% or more in all samples, as reported by analyses provided by the institution submitting the sample. Mononuclear cells from bone marrow or peripheral blood were isolated by isopycnic sedimentation through Ficoll-Hypaque (specific gravity 1.077 g/ml; Pharmacia, Piscataway, NJ, USA) at 400 g for 30 min followed by two washes with RPMI1640 medium.
Cell lines and plasmids
The neuroblastoma cell lines, Be2C and Be2C/ADR5 (Be2C cell line with an induced resistance to adriamycin) were generous gifts from Dr J Biedler (Memorial Sloan-Kettering Cancer Center, New York, NY, USA); the characterization of p16
INK4A in these cell lines has been described previously (Diccianni et al., 1996 (Diccianni et al., , 1999 . The Be2C, Be2C/ADR5 and the A549 lung cancer cell lines were cultured in the RPMI1640 medium supplemented with 10% fetal bovine serum (FBS) in 5% CO 2 . The osteosarcoma cell line U2OS was cultured in the Dulbecco's modified Eagles medium supplemented with 10% FBS. cDNAs of p16
INK4A and p16g for expression clone construction were generated by RT-PCR (see below) using RNA from the Be2C cell line. The amplified cDNAs of p16
INK4A and p16g were then separately cloned into pIND/V5-His-TOPO vector (Invitrogen, Carlsbad, CA, USA) to generate the pINDp16wt and pINDp16g expression constructs, respectively. The sequences of both pINDp16wt and pINDp16g were confirmed by DNA sequence analysis. The expression plasmids, pcp16wt or pcp16g, were constructed by ligation of the NheI-XboI fragments of the pINDp16wt or pINDp16g into pcDNA3.1( þ ) (Invitrogen) at the same restriction sites. The 3 Â WT E2F-Luc reporter plasmid, which contains three E2F response elements followed by a firefly luciferase reporter gene, has been described previously (Krek et al., 1993) . The phRG-TK plasmid and the phrGFP-C plasmid were purchased from Promega (Madison, WI, USA) and Stratagene (La Jolla, CA, USA), respectively.
RT-PCR for p16
INK4A and p16g Total RNA from cell lines and primary samples was extracted using the RNeasy kit (Qiagen, Valencia, CA, USA) or Trizol reagent (Invitrogen), and 2 mg of RNA was reverse-transcribed using the SuperScript II First-Strand Synthesis System for RT-PCR kit (Invitrogen). Expression analysis of full-length p16
INK4A and p16g was modified from a described previously procedure (Diccianni et al., 1996 (Diccianni et al., , 1999 (Diccianni et al., , 2004 , and performed using 10 pmol of each primer pair 5p16-S (5 0 -TGGAGC CTTCGGCTGACTGGCTGGC-3 0 ) and 3p16-AS (5 0 -CTAC GAAAGCGGGGTGGGTTGT-3 0 ) primers in an amplification reaction of 35 cycles of 30 s each at 95, 62, 721C in 1 Â Qiagen buffer containing 1 ml cDNA, 1.5 mM MgCl 2 , 40 mM 4dNTPs, 10% Q-solution (Qiagen), 2% dimethyl sulfoxide (DMSO) and 0.2 U Taq polymerase (Qiagen).
For cDNA cloning, full-length p16 INK4A and p16g were amplified from 1 ml of cDNA from the Be2C cell line using 10 pmol each of the PCR primer pair (p16-36S; 5 0 -GCAGC ATGGAGCCGGCGGCGG-3 0 ) and (p16-AS stop; 5 0 -GCC TCTCTGGTTCTTTCAATC-3 0 ) in an amplification mixture containing 1 Â Pfu polymerase buffer (Stratagene), 100 mM 4dNTPs, 1.5 mM MgCl 2 and 1 U Pfu polymerase (Stratagene). The samples were amplified for 35 cycles of 95, 501C and 301C of 30 s each, preceded by a 3 min denaturation at 951C, followed by a 5 min extension at 721C. We also designed PCR amplifications with primers exclusively in exon 2g to detect samples that may only weakly express p16g. The primers utilized for these assays include c447F (5 0 -GCACCAGAGGC AGTAACCAT-3 0 ) and I2737R (5 0 -GGTGCGGAGTGAGCC AGCCAG-3 0 ), which amplifies a 180 bp fragment of exon 2 and exon 2g and GAM517F (5 0 -GTGGGTTTGTAGAAGC AGGC-3 0 ) and 3p16T (5 0 -CTACGAAAGCGGGGTGGG TTGT-3 0 ), which amplifies a 318 bp fragment from the 5 0 regions of exon 2g and exon 3. Amplifications with these sets of primers were performed as described for expression cloning of p16 INK4A except that annealing was performed at 601C, and the c447F/I2737R primer pair amplification did not include DMSO.
Immunoprecipitation (IP) and western blot analysis IP and western blot analyses were performed as described previously with modifications (Diccianni et al., 1999; Lin et al., 2000) . At 48 h after transfection with each expression plasmid, A549, Be2C/ADR5 or U2OS cells in 60-mm dish were washed with phosphate-buffered saline (PBS) twice and lysed with 0.8 ml of IP lysis buffer (50 mM (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (HEPES), (pH 7.4), containing 0.1% NP-40, 200 mM NaCl, 2.5 mM ethylenediaminetetraacetic acid (EDTA), 1.0 mM dithiothreitol (DTT) and 1 Â protease inhibitor cocktail (Sigma, St Louis, MO, USA). An aliquot of 0.5 ml of cell lysate was immunoprecipitated with 2 ml of anti-CDK4 antibody (Santa Cruz Biotech Inc., Santa Cruz, CA, USA, sc-601) at 41C for 90 min, followed by 20 ml of protein A/G Agarose (Santa Cruz Biotech Inc., sc-2003) for another 90 min at 41C. The IP complex was resolved by 10 or 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and analysed by western blot for CDK4, p16
INK4A and p16g expression. Expression and purification of recombinant p16g and in vitro CDK4 inhibition assay The p16g gene was amplified by PCR using pIND-p16g DNA as template and 5 0 -CCCTGGGATCCATGGAGCCGGCGG CGG-3 0 and 5 0 -CCCGGGAATTCCCCTACGCATGCCTGC TTCTACAAACCC-3 0 as forward and reverse primers, respectively. After amplification, p16g was cloned into a pGEX-6p-1 vector (Amersham Biosciences) at BamHI and EcoRI sites and expressed in E. coli BL21 (DE3) codon plus cells (Stratagene) as a glutathione-S-transferase fusion protein (GST fusion protein). Bacteria harboring the pGEX-6p-1-p16g were grown at 371C in LB medium containing 100 mg/ml ampicillin and 34 mg/ml chloramphenicol to an OD 600 of 0.7, at which point the culture was cooled on ice for 7 min and isopropyl b-D-1-thiogalactopyranoside was added to a final concentration of 0.1 mM. After a 12 h incubation at room temperature, cells were spun down and resuspended in 50 ml of TES buffer (20 mM Tris-0.5 mM EDTA-0.15 M NaCl, pH 7.4), followed by sonication lysis. The lysate was then centrifuged at 41C for 1 h to remove debris, and the supernatant was loaded on a glutathione-agarose column (Sigma) that was pre-equilibrated using the above TES buffer. After washing with TES buffer, the resin was resuspended in 50 ml of TES containing 100 U of PreScission protease (Amersham Biosciences) and incubated at 41C for 16 h. Subsequently, the resin was repacked into a column, and the non-tagged p16g protein was eluted in the flow-through. The non-tagged p16g protein was concentrated and further purified on a S100 gel filtration column (Amersham Biosciences) equilibrated with 5 mM HEPES (pH 7.4), 1 mM EDTA and 1 mM DTT. After dialysis against the kinase buffer, 50 mM HEPES, 10 mM MgCl 2 , 2.5 mM EGTA, 0.1 mM Na 3 VO 4 , 1mM NaF, 10 mM b-glycerolphosphate, 1 mM DTT, 0.2 mM AEBSF, 2.5 mg/ml leupeptin and 2.5 mg/ml aprotinin (pH 7.4), p16g was aliquoted and stored at À201C.
The CDK4/cyclin D2 complex was expressed in insect cells infected with baculovirus, and purified as described previously (Byeon et al., 1998) . For the in vitro CDK4 kinase assay, each reaction mixture contained 3-10 U of CDK4/cyclin D2 and varying amounts of p16g protein in the kinase buffer in a final volume of 15 ml. After incubation at 301C for 30 min, 50 ng of GST-Rb791-928 (Li et al., 2003) and 5 mCi [g-32 P] adenosine triphosphate were added to the reaction mixture and incubated at 301C for another 15 min. The reaction was stopped by addition of 4 ml 5 Â SDS-PAGE loading buffer. Proteins in the reaction mixture were separated by 10% SDS-PAGE, using a Storm 840 Phosphoimager (Amersham Biosciences), and the incorporation of 32 P into GST-Rb791-928 was quantitatively evaluated using ImageQuant software (Amersham Biosciences). To quantitate the kinase activity, radioactive phosphate incorporation for the sample without an inhibitor (p16g or p16
INK4A proteins) was set as 100% CDK4 activity, and the incorporation measured for the mock sample (no CDK4) was used as background. The relative kinase inhibition activity is defined as (1ÀCDK4 activity with p16g or p16 plasmid, the latter of which was used for assessment of transfection efficiency. Two days after transfection, the cells were harvested and the luciferase activity was determined using Dual-Glo luciferase assay system (Promega) according to manufacturer's instructions.
Colony-forming assay
At 48 h after transfection with each expression and phrGFP-C plasmids, U2OS cells were trypsinized, washed and counted, and 3000 cells seeded in triplicate in 60-mm culture dishes. The remaining cells were analysed by FACS to determine the percentage of GFP-expressing cells, which represent the transfection efficiency. After 24 h incubation, plated cells were selected with 500 mg/ml of G418 (Invitrogen) and allowed to form colonies for 2 weeks. The colonies were fixed with 0.3% glutaraldehyde and stained with 1% methylene blue. The number of colonies larger than 1 mm in diameter in each dish was counted.
